Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

This study is ongoing, but not recruiting participants.

Study NCT00012233 Information provided by National Cancer Institute (NCI)

First Received: March 3, 2001 Last Updated: November 16, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study is ongoing, but not recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given

Publications:

Hurwitz HI, Zurlo A, Irl C, et al.: Analysis of outcomes of patients with metastatic colorectal cancer (mCRC) treated with IFL with or without bevacizumab (BV) in a phase III clinical trial based on baseline risk. [Abstract] American Society of Clinical Oncology 2006 Gastrointestinal Cancers Symposium, 26-28 January 2006, San Francisco, California. A-249, 2006.

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004 Jun 3;350(23):2335-42.